Effect of taurine supplementation on fat and bile acid absorption in patients with cystic fibrosis
- PMID: 3164502
- DOI: 10.3109/00365528809090237
Effect of taurine supplementation on fat and bile acid absorption in patients with cystic fibrosis
Abstract
Eleven children with cystic fibrosis (CF) and pancreatic insufficiency were given supplementation with taurine (30-40 mg/kg/day) for 2 months, while taking their usual dosage of enzymatic therapy. One patient dropped out of the study because she developed severe constipation. In the other 10 patients, urinary taurine excretion (88 +/- 30.1 mg/m2s.a./24 h) was similar to that of controls (86.2 +/- 6 mg/m2s.a./24 h) before taurine and increased markedly after supplementation (618.2 +/- 79.97 mg/m2s.a./24 h), indicating efficient intestinal absorption. Their coefficient of fat absorption was 81.2 +/- 2.3% and increased significantly after taurine (91.3 +/- 1.13%; p less than 0.01); the area under the curve of plasma triglyceride postprandial levels (1 +/- 0.1 mg X min/ml) also increased significantly after taurine (1.4 +/- 0.3 mg X min/ml; p less than 0.05), showing values very similar to those of controls. Conversely, no change was observed in the serum postprandial levels of glycocholic acid: the maximum postprandial peak before (1.2 +/- 0.3 mumol/l) and after taurine (1 +/- 0.1 mumol/l) remained significantly lower than in controls (2.4 +/- 0.3 mumol/l); p less than 0.01 and p less than 0.001, respectively. Mean total fecal bile acid (BA) excretion was 10.24 +/- 2.15 mg/kg/day before taurine and 12.8 +/- 4.27 mg/kg/day after taurine (normal pediatric values, 2.91 +/- 1.1 mg/kg/day); however, in the individual patients we found a variable trend, four of them showing a net increase in fecal BA excretion.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Taurine supplementation, fat absorption, and growth in cystic fibrosis.J Pediatr. 1987 Oct;111(4):501-6. doi: 10.1016/s0022-3476(87)80108-7. J Pediatr. 1987. PMID: 3309233 Clinical Trial.
-
Effect of taurine supplements on fat absorption in cystic fibrosis.Pediatr Res. 1985 Jun;19(6):578-82. doi: 10.1203/00006450-198506000-00015. Pediatr Res. 1985. PMID: 4011338 Clinical Trial.
-
Bile acid malabsorption in cystic fibrosis with and without pancreatic insufficiency.J Pediatr Gastroenterol Nutr. 1984 Sep;3(4):556-62. doi: 10.1097/00005176-198409000-00014. J Pediatr Gastroenterol Nutr. 1984. PMID: 6481566
-
Taurine supplementation in cystic fibrosis.Nutr Rev. 1988 Jul;46(7):257-8. doi: 10.1111/j.1753-4887.1988.tb05445.x. Nutr Rev. 1988. PMID: 3045705 Review. No abstract available.
-
Relationship between bile acid malabsorption and pancreatic insufficiency in cystic fibrosis.Gut. 1976 Apr;17(4):295-9. doi: 10.1136/gut.17.4.295. Gut. 1976. PMID: 773791 Free PMC article. Review.
Cited by
-
Thymopentin treatment in severe atopic dermatitis--clinical and immunological evaluations.Arch Dis Child. 1992 Sep;67(9):1095-102. doi: 10.1136/adc.67.9.1095. Arch Dis Child. 1992. PMID: 1329673 Free PMC article. Clinical Trial.
-
Cystic fibrosis, pathophysiological and clinical aspects.Eur J Pediatr. 1990 Aug;149(11):742-51. doi: 10.1007/BF01957271. Eur J Pediatr. 1990. PMID: 2226544 Review.
-
Clinical pharmacokinetics of therapeutic bile acids.Clin Pharmacokinet. 1996 May;30(5):333-58. doi: 10.2165/00003088-199630050-00002. Clin Pharmacokinet. 1996. PMID: 8743334 Review.
-
Enzyme contents of pancreatic extract preparations. Are they optimal?Drugs. 1992 Nov;44(5):685-9. doi: 10.2165/00003495-199244050-00001. Drugs. 1992. PMID: 1280561 Review. No abstract available.
-
A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis.PLoS One. 2019 Feb 22;14(2):e0212459. doi: 10.1371/journal.pone.0212459. eCollection 2019. PLoS One. 2019. PMID: 30794618 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical